Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And could be the reason for removal of dealership SMS web pages.
Attempting to hide references!?
https://web-beta.archive.org/web/20161017072000/http://dealerships.specmarksystems.com/
• HJOE DEALER ASKED ONLINE LAWYER FOR HELP
Dealers may be in trouble.
Why ask for contracts?
With all the shareholder investments...
...would've been much better to open up a IHOP or Denny's.
Then at least everyone could have had their fill of pancakes and waffles! AND the restaurant would likely still be open at this time!
I completely forgot about the MNK up to $1B share buyback.
Thats usually a good thing and shows a lot of confidence in management.
It sure feels like bottom, and Citron not complaining lately?
One would think that they would continue harping about MNK but they suddenly stop when its convenient for them.
Poor Amarillo TX shotdude cant get rid of it!
Still up for sale!
https://amarillo.craigslist.org/bfs/6006575669.html
...and we're helping him out advertising here and STILL can't sell at a massive "discount" OR BEST OFFER!
Its been, what, months now?
¡ROFL!
Yeah, Trump threats (veiled?) are going to be a big test for mid-large cap pharma companies. Reluctant to to invest in big companies until things resolve a bit more.
I got into QCOR in 2000, so that was $1 and change. Only sold a tiny bit to ride free shares way back then.
I'm still looking at small-cap pharma, emphasis on orphan drugs and companies with a good amount of reserve cash.
The company is still a decent buy, just don't rely on Acthar.
Licensing of Synacthen should put a damper on revs, but I don't know if there is a timetable for that to occur.
Possibly MNK has something sneaky up their sleeve, quick to pay off the $100M fine which isn't all THAT much (10% of Acthar revenue).
Maybe MNK just wanted to get FDA off their backs?
It will take time for recovery and the (somewhat) re-organzation towards the hospital field is very long-term positive. The other acquisitions will also offset Acthar diminishing returns if Synacthen is licensed.
KENNETH KARL FLETCHER ARREST MUGSHOT!
I missed this one, but its a goody!
Black shirts in vogue.
Another Brian Weber arrest mugshot!
This time a little classier w/black collar shirt. Where's the salmon colour power shirt? LOL!
https://www.vinelink.com/VineAppWebService/api/photo/?siteId=34003&agency=50&sid=136847320&imageType=front&subjectType=Offender&language=en
Exelixis, Inc. (EXEL) Rating Lowered to Hold at Stifel Nicolaus
Posted by Oliver Carreras on Feb 28th, 2017
Exelixis, Inc. (NASDAQ:EXEL) was downgraded by equities researchers at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday. They presently have a $22.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ target price indicates a potential downside of 4.72% from the company’s previous close. The analysts noted that the move was a valuation call.
Several other equities research analysts have also recently commented on EXEL. Cowen and Company reaffirmed an “outperform” rating on shares of Exelixis in a research report on Tuesday, November 8th. Zacks Investment Research raised Exelixis from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Monday, December 19th. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research report on Saturday, January 28th. Finally, Deutsche Bank AG began coverage on Exelixis in a research report on Thursday, November 3rd. They set a “buy” rating and a $17.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $16.76.
Analyst Recommendations for Exelixis (NASDAQ:EXEL)
Exelixis (NASDAQ:EXEL) traded down 3.38% on Tuesday, reaching $22.31. The company’s stock had a trading volume of 5,116,583 shares. The stock’s market cap is $6.39 billion. The stock has a 50-day moving average of $20.01 and a 200-day moving average of $15.30. Exelixis has a one year low of $3.55 and a one year high of $23.49.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, February 27th. The biotechnology company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.13. The business had revenue of $77.58 million for the quarter, compared to analysts’ expectations of $64.88 million. During the same period last year, the business earned ($0.19) earnings per share. The company’s quarterly revenue was up 680.7% on a year-over-year basis. On average, analysts predict that Exelixis will post ($0.44) EPS for the current fiscal year.
“Exelixis, Inc. (EXEL) Rating Lowered to Hold at Stifel Nicolaus” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/02/28/exelixis-inc-exel-downgraded-to-hold-at-stifel-nicolaus.html.
In other Exelixis news, Director George A. Scangos sold 204,894 shares of the stock in a transaction dated Wednesday, December 7th. The stock was sold at an average price of $17.81, for a total value of $3,649,162.14. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Gisela Schwab sold 22,000 shares of the stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $16.73, for a total value of $368,060.00. The disclosure for this sale can be found here. In the last three months, insiders sold 604,444 shares of company stock worth $10,413,061. 5.90% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of EXEL. BlackRock Institutional Trust Company N.A. increased its position in Exelixis by 7.7% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 5,770,563 shares of the biotechnology company’s stock worth $73,806,000 after buying an additional 413,100 shares in the last quarter. KCG Holdings Inc. increased its position in Exelixis by 2.2% in the third quarter. KCG Holdings Inc. now owns 130,582 shares of the biotechnology company’s stock worth $1,670,000 after buying an additional 2,780 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Exelixis during the third quarter worth $28,867,000. Rock Springs Capital Management LP purchased a new position in Exelixis during the third quarter worth $1,599,000. Finally, Allianz Asset Management AG increased its position in Exelixis by 30.2% in the fourth quarter. Allianz Asset Management AG now owns 1,091,543 shares of the biotechnology company’s stock worth $16,274,000 after buying an additional 253,123 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors.
About Exelixis
Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.
https://www.chaffeybreeze.com/2017/02/28/exelixis-inc-exel-downgraded-to-hold-at-stifel-nicolaus.html
Exelixis, Inc. Downgraded to Hold at Stifel Nicolaus
I guess this is the reason for the small drop. I'm not finding an explanation for the downgrade, I guess someone wants shares?
I believe its prelude to Trump State of Union speech.
A few BIOs got hit, threats of reduced drug prices and that garbage.
What model phone?
On my Android phone its usually the cache that mysteriously creeps up takes up a lot of room.
Facebook cache, photo cache, browser cache...
Usually in your phone settings there is a menu where you can view/examine your phone's storage and it breaks it down into categories. From there it may be possible to identify what is taking up most of your storage and also allows you to clear the cache.
Might as well just wad up the shares and use those to wipe.
Lemme get this straight...
People are investing in DIAPERS?
One of the few sources of advertising the jerkyoffs have.
Considering the company has no money to spend on ads.
What is fortunate is the more posts, the more it reveals to the public how scammy this company is (via popular searchable references).
Jerky critical reviews 3
Completely agree to this insight.
Seems to be a common tactic with scammy companies who do have a product that simply does not sell or is in demand.
Why would Bristol be culpable?
Doesn't seem forward looking when its definitive "will become".
Should have been something like "looking to become"?
The knowledgeable know this is a big scam.
Couldn't that be grounds for a lawsuit?
"Will become 1st retail grocery store customer", yet Bristol Farms did not complete the vendor cert within the 30 days. NHMD only sent them the forms, and of course Bristol Farms declined.
The lack of reviews is telling.
The last product review was 9 days ago.
Competitors receive reviews much more often than that.
Tough to "buy" Amazon reviews!
• Hangover Joe's Jerky wrong International trademark class!
They're still using International Class 005 - Pharmaceutical
They should also have International Class 029 - Meat, fish, poultry and game; meat extracts; preserved, dried and cooked fruits and vegetables; jellies, jams, fruit sauces; eggs, milk and milk products; edible oils and fats. - Meat, fish, poultry and game; meat extracts; preserved, dried and cooked fruits and vegetables; jellies, jams, fruit sauces; eggs, milk and milk products; edible oils and fats.
Wonder if this will cause problems?
https://trademarks.justia.com/857/09/hangover-joe-85709709.html
compare to Jack Link's:
https://trademarks.justia.com/869/80/jack-link-86980071.html
I'm not seeing a Korean Trademark?
http://engdtj.kipris.or.kr/engdtj/searchLogina.do?method=loginTM
Or Japan Trademark?
https://www3.j-platpat.inpit.go.jp/cgi-bin/ET/TM_LIST_E.cgi?ITEM01=106&KEY01=hangover+joe&OPT01=01&ITEM02=702&KEY02=&OPT02=01&ITEM03=402&KEY03=&OPT03=01&ITEM04=705&KEY04=&OPT04=01&STIME=148728794744235653805090&HITCNT=18&HITCNT3=18&S_FLAG=00&TERMOPT=02&PAGE=01
So that's why they're desperate to spend $100K?
They're hoping to bring in some Florida pump n dumpers?
LOL @ex-CEO via pm accusing me of shorting. Tough to do without a margin account! Demoted by your own company is HILARIOUS!